Breast Cancer: S1416 (Iowa Cancer Specialists)

Testing Cisplatin Given With ABT-888 Compared to Cisplatin Alone in Metastatic TNBC and BRCA Mutation-Associated Breast Cancer

Objective

The main purpose of this study is to compare any good and bad effects of using ABT-888 (Veliparib) (a “PARP” inhibitor) along with cisplatin to using cisplatin alone. This study is for patients that have metastatic triple negative breast cancer or have BRCA-mutation associated metastatic HER2 negative breast cancer.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Medical Center, West Central Park
    1401 West Central Park
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email